Unveiling 18 Analyst Insights On Moderna
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Moderna (NASDAQ:MRNA), with recent ratings showing a mix of bullish and bearish sentiments. The average 12-month price target has decreased by 20.12% to $102.44. Analysts have lowered their price targets, reflecting concerns over Moderna's financial performance, including a 30.06% revenue decline and negative profitability metrics.
October 15, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Moderna's stock is under scrutiny as analysts lower price targets, reflecting concerns over its financial performance. The average price target has dropped by 20.12%, indicating bearish sentiment. Financial challenges include a significant revenue decline and negative profitability metrics.
The article highlights a significant decrease in analysts' average price target for Moderna, reflecting a bearish outlook. This is compounded by financial challenges such as a 30.06% decline in revenue and negative profitability metrics, which are likely to impact the stock negatively in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100